Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124930192 | 12493019 | 2 | F | 2016 | 20160705 | 20160623 | 20160718 | EXP | CA-HQ SPECIALTY-CA-2016INT000403 | INTERCHEM | 75.00 | YR | F | Y | 0.00000 | 20160715 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124930192 | 12493019 | 1 | PS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | UNK | 201749 | |||||||||||
| 124930192 | 12493019 | 2 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 10 MG (5 MG, 2 IN 1 D) | Y | U | 0 | 5 | MG | ||||||
| 124930192 | 12493019 | 3 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 10 MG (5 MG, 2 IN 1 D) | Y | U | 0 | 5 | MG | ||||||
| 124930192 | 12493019 | 4 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 10 MG (5 MG, 2 IN 1 D) | Y | U | 0 | 5 | MG | ||||||
| 124930192 | 12493019 | 5 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 10 MG (5 MG, 2 IN 1 D) | Y | U | 0 | 5 | MG | ||||||
| 124930192 | 12493019 | 6 | SS | CELEBREX | CELECOXIB | 1 | UNK | 0 | |||||||||||
| 124930192 | 12493019 | 7 | C | PLAQUENIL /00072602/ | HYDROXYCHLOROQUINE DIPHOSPHATE | 1 | Oral | 400 MG (200 MG, 2 IN 1 D) | U | 0 | 200 | MG | |||||||
| 124930192 | 12493019 | 8 | C | SULFASALAZINE. | SULFASALAZINE | 1 | 2 G (1 G, 2 IN 1 D) | U | 0 | 1 | G |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124930192 | 12493019 | 1 | Rheumatoid arthritis |
| 124930192 | 12493019 | 2 | Rheumatoid arthritis |
| 124930192 | 12493019 | 6 | Rheumatoid arthritis |
| 124930192 | 12493019 | 7 | Rheumatoid arthritis |
| 124930192 | 12493019 | 8 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124930192 | 12493019 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124930192 | 12493019 | Cystitis | |
| 124930192 | 12493019 | Drug ineffective | |
| 124930192 | 12493019 | Impaired healing | |
| 124930192 | 12493019 | Lower respiratory tract infection | |
| 124930192 | 12493019 | Mobility decreased | |
| 124930192 | 12493019 | Nasopharyngitis | |
| 124930192 | 12493019 | Peripheral swelling | |
| 124930192 | 12493019 | Postoperative wound infection | |
| 124930192 | 12493019 | Viral infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124930192 | 12493019 | 2 | 20150428 | 20150525 | 0 | |
| 124930192 | 12493019 | 3 | 20160121 | 20160205 | 0 | |
| 124930192 | 12493019 | 4 | 20160411 | 0 | ||
| 124930192 | 12493019 | 5 | 20160418 | 20160511 | 0 | |
| 124930192 | 12493019 | 7 | 201606 | 0 | ||
| 124930192 | 12493019 | 8 | 201606 | 0 |